<DOC>
	<DOC>NCT00887627</DOC>
	<brief_summary>A study to compare a conivaptan PK in subjects with mild or moderate kidney function impairment to subjects with normal kidney function after a 48-hour continuous infusion of conivaptan.</brief_summary>
	<brief_title>Study to Compare Conivaptan Pharmacokinetics in Subjects With Mild &amp; Moderate Kidney Function Impairment to Subjects With Normal Kidney Function</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Hyponatremia</mesh_term>
	<mesh_term>Conivaptan</mesh_term>
	<criteria>Weighs at least 45 kg Body mass index between 18 and 40 kg/m2 inclusive Must be in good health other than renal function impairment and related stable diseases for the renal impaired subjects Must have a screening and predose estimated glomerular filtration rate (GFR) that corresponds with the level of renal impairment based on the abbreviated Modification of Diet in Renal Disease (MDRD) formula Female subject of childbearing potential must not be pregnant or lactating, must have a negative pregnancy test, utilizes adequate contraceptive methods while in this study or may be surgically sterile and/or two years post menopausal Subject is known to be HIV positive or has HIV antibodies Has clinically significant history or presence of illness, medical condition, or laboratory abnormality Is Hepatitis positive Subject with renal impairment has not been on a stable dose of concomitant medications for at least 4 weeks prior to start of study and/or dose changes are likely during the study History of substance abuse within 6 months prior to screening Has clinically significant history or presence of psychiatric illness, malignancy, or immunodeficiency syndrome Has abnormal liver function tests (ALT, AST, and/or bilirubin) Has had a blood transfusion or donated/lost more than 450ml of blood within 56 days of study drug administration or has donated plasma within 7 days prior to study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Protein Binding</keyword>
	<keyword>Conivaptan</keyword>
	<keyword>Vaprisol</keyword>
	<keyword>Kidney Diseases</keyword>
</DOC>